文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

预测重症急性坏死性胰腺炎患者的免疫增强治疗:多中心双盲随机对照试验

Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.
PubMed 文献 · Intensive Care Med · 2022-06-17
一句话结论预测重症急性坏死性胰腺炎患者早期使用胸腺肽α1并未降低本次住院期间感染性胰腺坏死的发生率(15.7% vs 18.1%,p=0.48)。

这项多中心、双盲、随机、安慰剂对照试验纳入508例预测重症急性坏死性胰腺炎患者(APACHE II评分≥8且CT严重度评分≥5,症状出现7天内入院),随机接受胸腺肽α1皮下注射(前7天1.6 mg每12小时一次,后7天1.6 mg每日一次)或安慰剂。主要终点为本次住院期间感染性胰腺坏死的发生,胸腺肽α1组40/254(15.7%)vs 安慰剂组46/254(18.1%),差异-2.4%(95%CI -7.4 to 5.1%),p=0.48。其他主要并发症如新发器官衰竭(10.6% vs 15%)、出血(6.3% vs 3.5%)、胃肠瘘(2% vs 2.4%)均无差异。结论提示免疫增强治疗未能降低感染性胰腺坏死发生率。

要点

  • 胸腺肽α1组感染性胰腺坏死15.7%(40/254)vs 安慰剂组18.1%(46/254),差异-2.4%(95%CI -7.4 to 5.1%),p=0.48,未达统计学显著。
  • 新发器官衰竭胸腺肽α1组10.6% vs 安慰剂组15%,出血6.3% vs 3.5%,胃肠瘘2% vs 2.4%,均无差异。
  • 四个预设亚组结果相似。
  • 94.3%(479/508)的患者需入住ICU。
  • 预测重症急性坏死性胰腺炎患者早期使用胸腺肽α1未降低本次住院期间感染性胰腺坏死发生率。

适用人群与场景

  • 预测重症急性坏死性胰腺炎患者,APACHE II评分≥8且CT严重度评分≥5,症状出现7天内入院。
  • 多数患者需入住ICU(479/508,94.3%)。

诊断标准与关键阈值

  • 预测重症急性坏死性胰腺炎:APACHE II评分≥8且CT严重度评分≥5。

处置流程与药物剂量

  • 胸腺肽α1组:皮下注射胸腺肽α1 1.6 mg,前7天每12小时一次,后7天1.6 mg每日一次;对照组给予匹配安慰剂(生理盐水)。

研究设计与关键结果

  • 多中心、双盲、随机、安慰剂对照试验,共纳入508例患者,胸腺肽α1组254例,安慰剂组254例。
  • 主要终点:本次住院期间感染性胰腺坏死发生率,胸腺肽α1组40/254(15.7%)vs 安慰剂组46/254(18.1%),差异-2.4%(95%CI -7.4 to 5.1%),p=0.48。
  • 四个预设亚组结果相似。
  • 其他主要并发症:新发器官衰竭胸腺肽α1组10.6% vs 安慰剂组15%;出血6.3% vs 3.5%;胃肠瘘2% vs 2.4%。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于预测重症急性坏死性胰腺炎患者,早期免疫增强胸腺肽α1治疗未能降低本次住院期间感染性胰腺坏死发生率,原文结论未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Infected pancreatic necrosis (IPN) is a highly morbid complication of acute necrotising pancreatitis (ANP). Since there is evidence of early-onset immunosuppression in acute pancreatitis, immune enhancement may be a therapeutic option. This trial aimed to evaluate whether early immune-enhancing Thymosin alpha 1 (Tα1) treatment reduces the incidence of IPN in patients with predicted severe ANP.

METHODS: We conducted a multicentre, double-blind, randomised, placebo-controlled trial involving ANP patients with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score ≥ 8 and a computed tomography (CT) severity score ≥ 5 admitted within 7 days of the advent of symptoms. Enrolled patients were assigned to receive a subcutaneous injection of Tα1 1.6 mg every 12 h for the first 7 days and 1.6 mg once a day for the subsequent 7 days or matching placebos (normal saline). The primary outcome was the development of IPN during the index admission.

RESULTS: A total of 508 patients were randomised, of whom 254 were assigned to receive Tα1 and 254 placebo. The vast majority of the participants required admission to the intensive care unit (ICU) (479/508, 94.3%). During the index admission, 40/254(15.7%) patients in the Tα1 group developed IPN compared with 46/254 patients (18.1%) in the placebo group (difference -2.4% [95% CI - 7.4 to 5.1%]; p = 0.48). The results were similar across four predefined subgroups. There was no difference in other major complications, including new-onset organ failure (10.6% vs. 15%), bleeding (6.3% vs. 3.5%), and gastrointestinal fistula (2% vs. 2.4%).

CONCLUSION: The immune-enhancing Tα1 treatment of patients with predicted severe ANP did not reduce the incidence of IPN during the index admission.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Ke L, Zhou J, Mao W, et al. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022. PMID: 35713670. doi:10.1007/s00134-022-06745-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。